Rattlesnake Envenomations Treated Without Antivenom

Thumbnail
Name:
Chang P_Poster.pdf
Size:
502.0Kb
Format:
PDF
Description:
Poster
Download
Thumbnail
Name:
ChangP_thesis.pdf
Size:
231.8Kb
Format:
PDF
Description:
Thesis
Download
Author
Chang, Phoebe
Affiliation
The University of Arizona College of Medicine - Phoenix
Issue Date
2018-03-28
Keywords
Rattlesnake
Anti-Venoms
Envenomation
MeSH Subjects
Crotalus
Antivenins
Snake Bites
Mentor
Curry, Steven

Metadata
Show full item record
Rights
Copyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
Collection Information
This item is part of the College of Medicine - Phoenix Scholarly Projects 2018 collection. For more information, contact the Phoenix Biomedical Campus Library at pbc-library@email.arizona.edu.
Publisher
The University of Arizona.
Abstract
The standard treatment for rattlesnake envenomation (RSE) is antivenom. The clinical course of patients treated with antivenom is well described. Prior to 2000, only a whole IgG AV (IgGAV) associated with high rates of hypersensitivity reactions (HSS) was available to treat RSE. Since 2000, Crotalidae Polyvalent Immune Fab (FabAV), which has a better safety profile than IgGAV, has been primarily used. Patients with RSE may not be treated with AV for a variety of reasons including history or perceived risk of HSS, patient refusal, drug shortage, or clinical impression that AV is not indicated. Research Question: What outcomes are associated with moderate to severe RSEs treated without antivenom?
Description
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
Collections